MIRM Overview

Mirum Pharmaceuticals, Inc. is a rare disease company with a global footprint of approved products and a pipeline of investigational medicines. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.

Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is102.33 USD with a low forecast of 81.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Mirum Pharmaceuticals Inc revenue for the last quarter amounts to 148.93M USD, increased 49.81

Mirum Pharmaceuticals Inc. EPS for the last quarter amounts to -0.11 USD, decreased -77.55

Mirum Pharmaceuticals Inc (MIRM) has 369 emplpoyees as of March 11 2026.

Today MIRM has the market capitalization of 5.49B USD.